Commentary
AKT inhibition: a bad AKT inhibitor in liver injury and tumor development?
Abstract
Cells respond to growth signals by activating internal programs that coordinate growth, division and death. One of these, the PI3K/AKT pathway, is frequently activated in human cancer (1). The serine/threonine kinase AKT is a key actor that regulates development, metabolism and the immune response (2,3).